




# PHARMACEUTICAL 2021

LEXICON PHARMACEUTICALS INC.  
Rank 136 of 402





RealRate

# PHARMACEUTICAL 2021

## LEXICON PHARMACEUTICALS INC. Rank 136 of 402



The relative strengths and weaknesses of LEXICON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LEXICON PHARMACEUTICALS INC. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 112% points. The greatest weakness of LEXICON PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 167%, being 120% points above the market average of 47%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 157,719           |
| Cost of Goods Sold                          | 1,929             |
| Intangible Assets                           | 44,543            |
| Liabilities, Current                        | 46,806            |
| Liabilities, Non-Current                    | 611               |
| Other Assets                                | 1,231             |
| Other Compr. Net Income                     | -90               |
| Other Expenses                              | 16,144            |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 136,355           |
| Other Revenues                              | 23,995            |
| Property and Equipment                      | 295               |
| Research and Development                    | 153,621           |
| Selling, General and Administrative Expense | 47,230            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 203,788           |
| Liabilities              | 47,417            |
| Expenses                 | 218,924           |
| Revenues                 | 23,995            |
| Stockholders Equity      | 156,371           |
| Net Income               | -58,574           |
| Comprehensive Net Income | -58,619           |
| Economic Capital Ratio   | 167%              |